Ocular Therapeutix (OCUL) Non-Current Debt (2013 - 2026)
Ocular Therapeutix (OCUL) posted quarterly Non-Current Debt of $72.8 million for Q2 2026, up 4.13% year-over-year from $69.9 million in Q2 2025, and up 1.02% on a QoQ basis from $72.1 million in Q1 2026.
Ocular Therapeutix (OCUL) Non-Current Debt (2013 - 2026) Analysis & Trends
Ocular Therapeutix has reported Non-Current Debt for 14 years, with the latest figure at $72.8 million in Q2 2026.
- Non-Current Debt for Q2 2026 came in at $72.8 million, up 4.13% year-over-year; the trailing twelve-month figure through Jun 2026 was $72.8 million (up 4.13% YoY), and the FY2025 annual result was $71.3 million, up 4.13% from the prior year.
- Non-Current Debt climbed to $72.8 million in Q2 2026, from $72.1 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $72.8 million in Q2 2026 and troughed at $23.3 million in Q2 2023.
- A 5-year average of $54.2 million and a median of $66.8 million in 2024 frame the typical range for Non-Current Debt.
- The widest annual swing landed in 2023, when Non-Current Debt retreated 7.26%; it then soared 188.08% in 2024.
- A 5-year view of Non-Current Debt shows it stood at $25.3 million in 2022, then jumped by 160.47% to $65.8 million in 2023, then rose by 4.13% to $68.5 million in 2024, then increased by 4.13% to $71.3 million in 2025, then increased by 2.05% to $72.8 million in 2026.
- Per Business Quant data, the three most recent Non-Current Debt figures were $72.8 million in Q2 2026, $72.1 million in Q1 2026, and $71.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Ocular Therapeutix | 2.20 Bn | 2.20 Bn | 11.46 Mn | 72.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 72.80 Mn |
| Mar 31, 2026 | 72.06 Mn |
| Dec 31, 2025 | 71.34 Mn |
| Sep 30, 2025 | 70.62 Mn |
| Jun 30, 2025 | 69.91 Mn |
| Mar 31, 2025 | 69.20 Mn |
| Dec 31, 2024 | 68.51 Mn |
| Sep 30, 2024 | 67.82 Mn |
| Jun 30, 2024 | 67.13 Mn |
| Mar 31, 2024 | 66.46 Mn |
| Dec 31, 2023 | 65.79 Mn |
| Sep 30, 2023 | 65.12 Mn |
| Jun 30, 2023 | 23.30 Mn |
| Mar 31, 2023 | 25.32 Mn |
| Dec 31, 2022 | 25.26 Mn |
| Sep 30, 2022 | 25.19 Mn |
| Jun 30, 2022 | 25.13 Mn |
| Mar 31, 2022 | 25.06 Mn |
| Dec 31, 2021 | 25.00 Mn |
| Sep 30, 2021 | 24.94 Mn |